Alexion Pharmaceuticals (ALXN) Trading Up 6.3% After Analyst Upgrade

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was up 6.3% during mid-day trading on Monday after BMO Capital Markets raised their price target on the stock from $177.00 to $180.00. BMO Capital Markets currently has an outperform rating on the stock. Alexion Pharmaceuticals traded as high as $115.98 and last traded at $115.43. Approximately 2,651,232 shares were traded during mid-day trading, an increase of 26% from the average daily volume of 2,110,139 shares. The stock had previously closed at $108.60.

Several other research firms have also commented on ALXN. Zacks Investment Research upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating and set a $144.00 price target for the company in a report on Tuesday, October 31st. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, December 27th. Citigroup reduced their price target on shares of Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a report on Friday, February 9th. Stifel Nicolaus restated a “buy” rating and issued a $151.00 price target on shares of Alexion Pharmaceuticals in a report on Friday, February 9th. Finally, Deutsche Bank set a $161.00 price target on shares of Alexion Pharmaceuticals and gave the company a “buy” rating in a report on Friday, February 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and twenty-one have assigned a buy rating to the company’s stock. Alexion Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $152.77.

In related news, SVP Heidi L. Wagner sold 655 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $117.26, for a total transaction of $76,805.30. Following the completion of the transaction, the senior vice president now owns 32,635 shares in the company, valued at approximately $3,826,780.10. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ludwig Hantson sold 2,553 shares of the business’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. In the last quarter, insiders have sold 28,930 shares of company stock valued at $3,378,199. 4.35% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Ameriprise Financial Inc. increased its stake in Alexion Pharmaceuticals by 3.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 6,390,301 shares of the biopharmaceutical company’s stock valued at $896,491,000 after purchasing an additional 215,005 shares in the last quarter. Jennison Associates LLC increased its stake in Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Geode Capital Management LLC increased its stake in Alexion Pharmaceuticals by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 2,256,415 shares of the biopharmaceutical company’s stock valued at $269,251,000 after purchasing an additional 62,266 shares in the last quarter. UBS Asset Management Americas Inc. increased its stake in Alexion Pharmaceuticals by 10.3% during the 4th quarter. UBS Asset Management Americas Inc. now owns 1,871,548 shares of the biopharmaceutical company’s stock valued at $223,818,000 after purchasing an additional 174,606 shares in the last quarter. Finally, Wells Fargo & Company MN increased its stake in Alexion Pharmaceuticals by 32.7% during the 3rd quarter. Wells Fargo & Company MN now owns 1,558,531 shares of the biopharmaceutical company’s stock valued at $218,647,000 after purchasing an additional 383,713 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

The company has a current ratio of 3.10, a quick ratio of 2.62 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $25,270.00, a P/E ratio of 57.85, a PEG ratio of 0.95 and a beta of 1.16.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a net margin of 12.48% and a return on equity of 12.94%. The business had revenue of $909.70 million for the quarter, compared to analyst estimates of $880.38 million. During the same quarter in the prior year, the business posted $1.26 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 9.5% compared to the same quarter last year. sell-side analysts expect that Alexion Pharmaceuticals, Inc. will post 6.25 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Alexion Pharmaceuticals (ALXN) Trading Up 6.3% After Analyst Upgrade” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://transcriptdaily.com/2018/02/14/alexion-pharmaceuticals-alxn-trading-up-6-3-after-analyst-upgrade.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply